Magellan COMPLETE CARE®

HEDIS®[1]: Statin Therapy for Patients with Cardiovascular Disease (SPC)

Description of the measure

Males 21-75 years old and females 40-75 years old with clinical atherosclerotic cardiovascular disease (ASCVD) who were dispensed at least one moderate to high-intensity statin during the measurement year. These patients are monitored to remain adherent for at least 80% of the treatment period during the year.

Exclusion(s)

- ❑ Pregnancy*
- ❑ In vitro fertilization (IVF)*
- ❑ Prescription of clomiphene*
- ❑ End-stage renal disease (ESRD)*
- ❑ Cirrhosis*
- ❑ Myalgia, myositis, myopathy, or rhabdomyolysis during the measurement year
- ❑ Palliative care during the measurement year

** During the measurement year or year prior*

Tips for best practice

- ❑ If appropriate, prescribe at least a moderate-intensity statin for patients with ASCVD
- ❑ If not appropriate, please state the reason for contraindication in the medical record
- ❑ Patients with a history of statin-associated myopathy may better tolerate medications with a lower incidence of muscle-related adverse events (e.g. Pravastatin or Fluvastatin)[2]
- ❑ Encourage patient adherence by prescribing 90-day supply

Description	Prescription of statin	
Moderate intensity	Atorvastatin 10-20 mg Simvastatin 20-40 mg Lovastatin 40 mg Pravastatin 40-80 mg	Pitavastatin 2-4 mg Rosuvastatin 5-10 mg Fluvastatin 40 mg Fluvastatin XL 80 mg
High intensity	Atorvastatin 40-80 mg	Rosuvastatin 20-40 mg

[1] HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

[2] Bruckert, et al. Cardiovasc Drug Ther, 200